Sunstone
  • Home
  • What We Do
  • Investment Strategy
  • Funds
  • People
  • Business Development Advisory Board
  • Portfolio
  • News & Insights
  • Download Area
  • Contact
Select Page

Teitur Trophics Raises EUR 28M in Series A Financing to advance the development and treatment for neurodegenerative diseases

14/03/2023

Teitur Trophics Raises EUR 28M in Series A Financing to advance the development and treatment for neurodegenerative diseases Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases,...

Ascelia Pharma meets major milestone with patient enrollment completion for Orviglance Phase 3 Study, SPARKLE

24/02/2023

Ascelia Pharma meets major milestone with patient enrollment completion for Orviglance Phase 3 Study, SPARKLE Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the successful...

MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine

05/01/2023

MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces...

Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate

03/01/2023

Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces strong interim results from the ongoing...

Alligator Bioscience and Orion Corporation announce the initiation of the second program of their Immuno-oncology Research Collaboration and License Agreement

03/01/2023

Alligator Bioscience and Orion Corporation announce the initiation of the second program of their Immuno-oncology Research Collaboration and License Agreement Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces an expansion to its research collaboration and...

MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus

16/12/2022

MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the successful...
Side 3 af 5«12345»

Recent Posts

  • Biotech ecosystem contributors!
  • Do local investors make a difference?
  • Seed & Series A in Denmark
  • Treetop Meeting
  • Hans T. Scambye joins Sunstone as Venture Partner

Recent Comments

    Archives

    • January 2026
    • December 2025
    • August 2025
    • January 2025
    • September 2024
    • July 2024
    • May 2024
    • March 2024
    • February 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    • July 2023
    • April 2023
    • March 2023
    • February 2023
    • January 2023
    • December 2022
    • October 2022
    • September 2022
    • June 2022
    • March 2022
    • February 2022
    • January 2022
    • November 2021
    • October 2021
    • September 2021
    • August 2021
    • May 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • September 2019
    • July 2019
    • May 2019
    • March 2019
    • February 2019

    Categories

    • Ikke-kategoriseret
    • Insights
    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Supported by:

    Member of:

    Cookie Policy
    Privacy Policy
    CSR Policy
    Tax Policy

    Supported by:

    Member of:

    Cookie Policy
    Privacy Policy
    CSR Policy
    Tax Policy

    Sustainability-related disclosures    ·     No consideration of sustainability adverse impacts
    Design TR-Media ApS ©2021

    We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
    Cookie settingsAccept
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT